A5007290313- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- DNA Repair Mechanisms
- Frailty in Older Adults
- Chronic Lymphocytic Leukemia Research
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- bioluminescence and chemiluminescence research
- Chromatin Remodeling and Cancer
- Cancer Risks and Factors
- Computational Drug Discovery Methods
- Genetic factors in colorectal cancer
- Mechanisms of cancer metastasis
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Breast Lesions and Carcinomas
Royal Marsden Hospital
2005-2025
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2017-2024
Breast Cancer Care
2023
Breast Cancer Now
2023
National Health Service
2018-2020
Government of the United Kingdom
2020
University College London
2011-2018
The Christie NHS Foundation Trust
2018
Cambridge University Hospitals NHS Foundation Trust
2018
<h3>Importance</h3> Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients at risk relapse. <h3>Objective</h3> To assess the clinical validity molecular relapse detection with circulating tumor DNA (ctDNA) analysis in early-stage <h3>Design, Setting, and Participants</h3> This prospective, multicenter, sample collection, validation study conducted 5 United Kingdom medical centers from November 24, 2011,...
BackgroundCirculating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile advanced cancer, without need to repeat biopsy. We aimed assess accuracy ctDNA in breast cancer and ability select patients for mutation-directed therapy.MethodsWe did an open-label, multicohort, phase 2a, platform trial 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed Eastern Cooperative Oncology Group performance status 0–2. Patients had...
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of palbociclib plus letrozole as neoadjuvant PATIENTS AND METHODS Postmenopausal women ER-positive primary BC and tumors greater than or equal 2.0 cm were randomly assigned 3:2:2:2 (2.5 mg/d) for 14 weeks (A); 2 weeks, then (B); (C); weeks. Palbociclib 125 mg/d was administered orally...
The aim of this study was to ascertain if oestrogen receptor (ER) status predicts for pathological complete response (pCR) neoadjuvant chemotherapy in operable breast cancer, and the effects pCR on survival. Using a single-institution database, 435 patients were identified, who received cancer eligible analysis. Patients whose tumours ER negative more likely achieve than positive (21.6 vs 8.1%, P<0.001). Owing strong correlation between grade, these variables not shown be independent...
This study compares the sensitivities and specificities of three techniques for detection circulating epithelial cells in blood patients with breast cancer. The number present 40 metastatic cancer 20 healthy volunteers was determined by: immunomagnetic separation (IMS) laser scanning cytometry (LSC), cell filtration LSC a multimarker real-time RT–PCR assay. Numbers cytokeratin-positive identified expression PCR markers were significantly higher than volunteers. Using upper 95% confidence...
There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has potential be an effective adjuvant cancer therapy.
Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast evolves with time and under selective pressure treatment, potential acquire mutations resistance treatment disease progression. To identify potentially targetable in advanced cancer, we performed prospective characterization a cohort patients ABC.Biopsies from were sequenced 41 genes targeted panel ABC Biopsy (ABC-Bio) study. Blood samples collected at progression for...
Abstract The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating DNA sequencing to interrogate the genomic profile ABC in 800 patients plasmaMATCH trial. We demonstrate diverse subclonal resistance mutations, including enrichment HER2 mutations positive disease, co-occurring ESR1 MAP kinase pathway HR + HER2− disease that associate...
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
IntroductionOlder patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of for EBC quality life in older are limited, this is a key determinant treatment acceptance. We aimed to investigate its effect enrolled Bridging Age Gap study.Materials and methodsA prospective, multicentre, observational study ≥70 years old was conducted 2013–2018 at 56 UK hospitals. Demographics, patient, tumour characteristics,...
Although a common challenge for patients and clinicians, there is little population-level evidence on the prevalence of cardiovascular disease (CVD) in individuals diagnosed with potentially curable cancer.We investigated CVD rates malignancies evaluated associations between patient characteristics prevalence.The study included cancer registry England stage I to III breast cancer, colon or rectal prostate IIIA non-small-cell lung IV diffuse large B-cell lymphoma, Hodgkin lymphoma from 2013...
512 Background: NATALEE assessed ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with HR+/HER2− EBC at increased risk of recurrence, including N0 disease, and showed a statistically significant invasive disease-free survival (iDFS) benefit. We report BL characteristics, efficacy, safety for the subgroup. Methods: Pts stage II/III were randomized (R) 1:1 to RIB 400 mg/d (3 wk on/1 off 36 mo) (letrozole or anastrozole ≥60 alone. Men premenopausal women received...
1010 Background: Circulating tumor DNA (ctDNA) based detection of Molecular Residual Disease (MRD) in breast cancer patients presents a strategy to identify at high risk relapse, although current assays have limited sensitivity for low level ctDNA detection. In this study we profile early with an ultra-sensitive, whole genome sequencing-based, tumor-informed platform, and correlate the findings clinical outcomes. Methods: We analysed 598 plasma samples (median 8 samples/patient, range 2-14)...
Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma a better overall survival than those with disease. Many classification systems assessing pathological response to include ductal in situ (DCIS) only the definition of complete response. The purpose this study was investigate whether patients DCIS same prognosis as or A retrospective analysis prospectively maintained database identified 435 patients, received operable between February 1985...
Abstract Background Epithelial cells may be detected in the circulation of majority patients with metastatic breast cancer. Quantification such presumptive cancer might allow for monitoring early or late stage disease as an index relapse. Additionally, biomarker analysis a more rational approach to therapeutics. We have developed new method detection and characterisation these cells. Methods Blood was filtered through polycarbonate membranes containing cylindrical pores, 8 μm diameter. All...
BackgroundAge-related breast cancer treatment variance is widespread with many older women having primary endocrine therapy (PET), which may contribute to inferior survival and local control. This propensity-matched study determined if a subgroup of safely be offered PET.MethodsMulticentre, prospective, UK, observational cohort analysis determine optimal allocation surgery plus ET (S+ET) or PET in aged ≥70 cancer. Data on fitness, frailty, stage, grade, biotype, quality life were collected....